Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Heffernan

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Drugs in Dermatology : JDD|March 22, 2007
A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planusMichael P Heffernan, David I Smith, Danette Bentley, et al.
Archives of Dermatology|November 23, 2006
Successful treatment of mucous membrane pemphigoid with etanercept in 3 patientsMaria J Canizares, David I Smith, Michael S Conners, et al.
Archives of Dermatology|December 21, 2005
Alefacept for alopecia areataMichael P Heffernan, Maria Yadira Hurley, Kathleen S Martin, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
The Journal of Investigative Dermatology|July 8, 2014
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient bloodClaire Q F Wang, Mayte Suárez-Fariñas, Kristine E Nograles, et al.
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|April 4, 2016
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture ElutionTalia M Muram, John H Sloan, Jana S Chain, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|February 28, 2004
A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgarisJames Leyden, Wilma Bergfeld, Lynn Drake, et al.
The British Journal of Dermatology|February 6, 2023
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology SocietyMatthew A Pimentel, May M Li, Megan H Noe, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Drugs in Dermatology : JDD|March 22, 2007
A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planusMichael P Heffernan, David I Smith, Danette Bentley, et al.
Archives of Dermatology|November 23, 2006
Successful treatment of mucous membrane pemphigoid with etanercept in 3 patientsMaria J Canizares, David I Smith, Michael S Conners, et al.
Archives of Dermatology|December 21, 2005
Alefacept for alopecia areataMichael P Heffernan, Maria Yadira Hurley, Kathleen S Martin, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
The Journal of Investigative Dermatology|July 8, 2014
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient bloodClaire Q F Wang, Mayte Suárez-Fariñas, Kristine E Nograles, et al.
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|April 4, 2016
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture ElutionTalia M Muram, John H Sloan, Jana S Chain, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
Journal of the American Academy of Dermatology|February 28, 2004
A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgarisJames Leyden, Wilma Bergfeld, Lynn Drake, et al.
The British Journal of Dermatology|February 6, 2023
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology SocietyMatthew A Pimentel, May M Li, Megan H Noe, et al.
Pageof 4